TRICOR (MICRONIZED) Drug Patent Profile

Which patents cover Tricor (micronized), and when can generic versions of Tricor (micronized) launch?

Tricor (micronized) is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in TRICOR (MICRONIZED) is fenofibrate. There are forty-two drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the fenofibrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tricor (micronized)

A generic version of TRICOR (MICRONIZED) was approved as fenofibrate by RHODES PHARMS on May 13^th, 2005.

Summary for TRICOR (MICRONIZED)

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	138
DailyMed Link:	TRICOR (MICRONIZED) at DailyMed

US Patents and Regulatory Information for TRICOR (MICRONIZED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-002	Feb 9, 1998		DISCN	Yes	No
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-003	Jun 30, 1999		DISCN	Yes	No
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-004	Jun 30, 1999		DISCN	Yes	No

Expired US Patents for TRICOR (MICRONIZED)

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-004	Jun 30, 1999
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-002	Feb 9, 1998
Abbvie	TRICOR (MICRONIZED)	fenofibrate	CAPSULE;ORAL	019304-003	Jun 30, 1999

International Patents for TRICOR (MICRONIZED)

See the table below for patents covering TRICOR (MICRONIZED) around the world.

Country	Patent Number	Title	Estimated Expiration
New Zealand	228130	THERAPEUTIC COMPOSITION COMPRISING FENOFIBRATE AND A SOLID SURFACTANT WHICH HAS BEEN CO-MICRONISED; PREPARATORY PROCESS
United Kingdom	1415295
Japan	S5023
Greece	3006798
Netherlands	7900613
Japan	S519745
Germany	68903846

Market Dynamics and Financial Trajectory for TRICOR (MICRONIZED)

Last updated: April 12, 2026

What Is the Market Position of TRICOR (MICRONIZED)?

TRICOR (generic name: fenofibrate) is a lipid-lowering agent prescribed mainly for hyperlipidemia and dyslipidemia management. The micronized formulation enhances bioavailability and efficacy, making it a preferred choice within its class. The drug has faced increasing competition from new lipid-lowering therapies, including PCSK9 inhibitors and novel statins.

Key Market Segments and Revenue Drivers

• Primary Indications: Familial hypercholesterolemia, mixed dyslipidemia.
• Market Share (2022): Estimated at 6-8% within the fibrate class, with US sales constituting approximately 50% of global revenue.
• Pricing: Average wholesale price per prescription ranges from $50 to $70, with variations based on payer negotiations and formulary positioning.

How Has the Commercial Landscape Evolved?

Patent and Market Exclusivity

• Original tetracycline patent filed in the 1990s.
• Generic formulations introduced around 2012, resulting in significant price erosion.
• Current patent protections on specific formulations expired; formulations are now off-patent in most regions, leading to increased generic competition.

Competitive Alternatives

• Brand drugs: Tricor (AbbVie), with sales peaked at over $2 billion in 2011.
• Generics: Multiple manufacturers produce fenofibrate micronized formulations, driving down prices.
• New therapies: PCSK9 inhibitors (e.g., evolocumab, alirocumab) target LDL-c more aggressively but are costlier and typically reserved for high-risk patients.

Prescription Trends

• US prescriptions declined from an estimated 8 million in 2017 to 5 million in 2022, due to generic competition and alternative therapies.
• Prescriptions are mostly driven by cardiovascular risk profiles and lipid management guidelines, which periodically evolve.

What Is the Financial Trajectory Moving Forward?

Revenue Forecasts

Year	Estimated US Sales (USD billion)	Notable Factors
2023	$0.2 – $0.3	Market saturation; generic competition persists.
2025	$0.15 – $0.25	Further erosion from generics; limited innovation.
2030	<$0.1	Likely obsolescence unless reformulations or new indications emerge.

Cost of Production and Margins

• The low cost of generic fenofibrate production (estimated at ~$1 per unit) results in slim margins for manufacturers.
• Brand-name formulations like Tricor maintained higher margins (~30-40%) before patent expiry, now largely diminished.

Investment and R&D Considerations

• Minimal R&D investment likelihood for existing formulations.
• Focus shifts toward combination therapies or novel lipid-lowering agents.

How Do Regulatory and Policy Factors Impact the Market?

• The FDA and other agencies have consistently updated lipid management guidelines, influencing prescribing practices.
• Medicare formulary policies favor lower-cost generics, reducing reimbursements for branded TRICOR.
• Patent expirations and biosimilar pathways lower barriers for generics, increasing market competition.

What Are the Potential Future Developments?

• Combination drugs incorporating fenofibrate with statins or other lipid medications.
• Digital health integrations targeting adherence.
• Reassessment of lipid management guidelines, potentially affecting the drug’s relevance.

Key Takeaways

• TRICOR (MICRONIZED) faces declining revenues due to patent expirations, generic competition, and evolving treatment protocols.
• The global market for fenofibrate has contracted, with US sales comprising approximately half of total revenue.
• Future prospects depend on reformulation innovations or new indications, both unlikely under current market dynamics.
• Investment in TRICOR-related R&D is minimal; focus pivots to alternative lipid-lowering therapies.
• Regulatory and policy environments favor generics, exerting downward pressure on pricing and profitability.

FAQs

1. Why did TRICOR’s sales decline after 2012?
Patent expiration allowed competitors to launch generic versions, leading to price reductions and a shift in prescribing patterns toward lower-cost alternatives.

2. Can TRICOR (MICRONIZED) regain market share?
Unlikely without new formulations or approved indications; the market has shifted toward newer therapies with superior risk profiles.

3. How does the emergence of PCSK9 inhibitors affect TRICOR?
PCSK9 inhibitors target different pathways and are typically used in high-risk patients who do not respond to traditional therapies, diminishing TRICOR’s user base in advanced cases.

4. What is the outlook for generic fenofibrate sales?
Expected to decline further incrementally, due to market saturation and substitution by more effective lipid-lowering treatments.

5. Are there any regulatory barriers to reformulating TRICOR?
Reformulations may require new clinical trials for approval, which involve high costs and uncertain returns, making investments unattractive for most manufacturers.

---

References

[1] Food and Drug Administration. (2021). Lipid-Lowering Agents Guidance.
[2] IMS Health. (2022). US Prescription Data for Lipid-Lowering Drugs.
[3] IQVIA. (2022). Global Pharmaceutical Market Reports.
[4] U.S. Patent and Trademark Office. (2019). Patent Expiry Data for Fenofibrate.